SPOTLIGHT -
Dr. Narayan on efficacy, tolerability of nadofaragene firadenovec in BCG-unresponsive NMIBC
Vikram M. Narayan, MD, discusses the high complete response rate and manageable safety profile with nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer.
Genetic Testing in Metastatic Prostate Cancer
Genetic Testing in Localized Prostate Cancer
Gene Testing Criteria in Prostate Cancer
Germline Mutations & the 2-Hit Theory in Prostate Cancer
Tobacco cessation critical to preventing bladder cancer recurrence
Vikram M. Narayan, MD, discusses how smoking is the most significant known risk factor for bladder cancer.
Kidney stone population management program yields several benefits
Reza Z. Goharderakhshan, MD, discusses how patient compliance for recommended studies increased from less than 10% to 82% following implementation of the program.
Dr. Giulia Lane discusses urethral stricture disease in women
On the latest episode of the Speaking of Urology podcast, Dr. Giulia Lane discusses her recent study evaluating treatment of urethral stricture disease in women.
Patient counseling for mesh mid-urethral sling surgery: Provide options, set expectations
“Listen. Be emphatic. Be transparent,” Pansy Uberoi, MD, MPH, advises in this interview.
Dr. Adam J. Gadzinski describes the emergence of precision medicine in prostate cancer
Urologist Adam J. Gadzinski, MD, MS, shares his excitement about the dawn of the precision medicine era in prostate cancer.
Attorney Kenton H. Steele, Esq discusses informal prescribing
Steele outlines topics covered in his recent column, "Why urologists should beware the perils of friendly prescribing."
PSMA PET/CT impact on upstaging and reducing equivocal findings in prostate cancer
Declan G. Murphy, MB BCh, discusses how PSMA PET/CT imaging often leads to the upstaging of a patient’s prostate tumor, as well as how the novel technique lowers the rate of equivocal findings.
COVID-19 and Treating Metastatic Castration-Resistant Prostate Cancer
The Role of PARP Inhibitors in Prostate Cancer
A Look at the PROfound Trial
Newly Approved Agents for Metastatic Castration-Resistant Prostate Cancer
Genetic Testing: A Conversation with Your Patient
Genetic Testing in Metastatic Castration-Resistant Prostate Cancer
Overview of Metastatic Castration-Resistant Prostate Cancer
Dr. Ramaprasad Srinivasan on the HIF-2α inhibitor MK-6482 in VHL-associated RCC
Over 90% of patients in a phase 2 trial had at least some decrease in the size of target lesions.
Decline seen in Medicare reimbursement for men's health procedures
Victoria S. Edmonds and Tobias Köhler, MD, MPH, discuss trends in reimbursement for men's health procedures from 2002 to 2020.
Dr. Ramaprasad Srinivasan highlights the latest treatment advances in kidney cancer
The comprehensive review includes key developments in both clear cell and non-clear cell histology.
Dr. Declan G. Murphy describes the background of PSMA PET/CT in prostate cancer
Murphy shares the backstory of how PSMA PET/CT imaging has emerged as a major advancement in the prostate cancer armamentarium.
Dr. Leonard Gomella on bladder cancer advances in 2020
Gomella looks back on the year's top headlines in bladder cancer, from FDA approvals to notable clinical trial results.
Nadofaragene firadenovec and the future of NMIBC care
Dr. Vikram M. Narayan describes treatment advances and next steps in non-muscle invasive bladder cancer.
Disparities in urologic care and how telemedicine can help mitigate them
Urologist Adam J. Gadzinski, MD, MS, shares how telemedicine can help improve access to urologic care.
How has the COVID-19 pandemic presented challenges in conducting clinical trials?
Angela B. Smith, MD, MS, discusses how her institution has adjusted how it conducts clinical trials in the COVID-19 era.
Dr. Vikram M. Narayan on subgroup analyses of nadofaragene firadenovec in NMIBC
The analyses are from a pivotal phase 3 trial of nadofaragene firadenovec which previously met its primary end point of complete response.
Management of high-risk NMIBC: Options for treatment expand
“As urologists, we all need to start speaking in risk stratification criteria,” says Katie Murray, DO.
Jelmyto for low-grade UTUC: Clinical experience and side effects to watch for
Angela B. Smith, MD, MS, describes her institution’s early clinical experience with mitomycin-containing reverse thermal gel (Jelmyto).